Task force 2: Investigator participation in clinical research

Because cardiovascular disease is the leading cause of death and disability in the technologically developed world (1) and is projected to increase in prevalence over the next 30 years, appropriate ethical behavior by cardiovascular HCPs could have a major impact on the well-being of both individual...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2004-10, Vol.44 (8), p.1729-1736
Hauptverfasser:	Califf, Robert M., Nissen, Steven E., DeMaria, Anthony N., Ohman, Erik Magnus, Pitt, Bertram, Willerson, James T., Bilheimer, David W., Cohn, Jay N., Feigal, David W., Hampson, Lindsay, Lorell, Beverly H., Pepine, Carl J., Popp, Richard L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Advisory Committees Bias Bioethics Cardiology Cardiovascular disease Cardiovascular Diseases - therapy Clinical trials Clinical Trials as Topic - legislation & jurisprudence Conflict of Interest - legislation & jurisprudence Data Collection - statistics & numerical data Ethics Ethics, Medical Humans Medical technology Participation Pharmaceutical industry Principles Public access Public private partnerships Research Design Societies, Medical Studies Technological change United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Because cardiovascular disease is the leading cause of death and disability in the technologically developed world (1) and is projected to increase in prevalence over the next 30 years, appropriate ethical behavior by cardiovascular HCPs could have a major impact on the well-being of both individuals and society. [...]when considering the relationship between industry and the profession, one should not dismiss non-financial sources of bias and conflict, but should consider the whole spectrum of conflict.
ISSN:	0735-1097 1558-3597
DOI:	10.1016/j.jacc.2004.08.039